VolitionRX (NYSEAMERICAN:VNRX) Stock Price Passes Below Fifty Day Moving Average – Here’s What Happened

VolitionRX Limited (NYSEAMERICAN:VNRX) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $0.25 and traded as low as $0.1922. VolitionRX shares last traded at $0.20, with a volume of 678,812 shares traded.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Maxim Group downgraded shares of VolitionRX from a “buy” rating to a “hold” rating in a research note on Wednesday, December 3rd. D. Boral Capital reiterated a “buy” rating and set a $3.00 price target on shares of VolitionRX in a research report on Wednesday, January 21st. Finally, HC Wainwright decreased their price objective on shares of VolitionRX from $2.50 to $1.50 and set a “buy” rating on the stock in a research note on Monday, November 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $2.50.

VolitionRX Stock Down 1.3%

The firm has a 50 day moving average of $0.25 and a two-hundred day moving average of $0.38. The firm has a market capitalization of $27.11 million, a price-to-earnings ratio of -0.87 and a beta of 1.33.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Lagoda Investment Management L.P. boosted its holdings in shares of VolitionRX by 6.7% during the 3rd quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the medical research company’s stock valued at $8,476,000 after acquiring an additional 782,000 shares in the last quarter. Virtu Financial LLC increased its holdings in VolitionRX by 166.6% in the 4th quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock worth $28,000 after purchasing an additional 67,848 shares in the last quarter. Squarepoint Ops LLC acquired a new position in VolitionRX in the 4th quarter worth about $34,000. Citadel Advisors LLC raised its position in VolitionRX by 70.1% in the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after purchasing an additional 135,775 shares during the last quarter. Finally, Armistice Capital LLC boosted its stake in shares of VolitionRX by 10.4% during the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock valued at $6,367,000 after purchasing an additional 887,351 shares in the last quarter. 8.09% of the stock is currently owned by institutional investors and hedge funds.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.